MACK Stock Overview
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company.
Merrimack Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.25|
|52 Week High||US$7.41|
|52 Week Low||US$3.66|
|1 Month Change||-12.06%|
|3 Month Change||-15.32%|
|1 Year Change||-18.61%|
|3 Year Change||-16.00%|
|5 Year Change||-84.56%|
|Change since IPO||-91.31%|
Recent News & Updates
Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|MACK||US Biotechs||US Market|
Return vs Industry: MACK exceeded the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: MACK underperformed the US Market which returned -11.5% over the past year.
|MACK Average Weekly Movement||8.1%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: MACK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MACK's weekly volatility (8%) has been stable over the past year.
About the Company
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals Fundamentals Summary
|MACK fundamental statistics|
Is MACK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MACK income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.14|
|Net Profit Margin||0.00%|
How did MACK perform over the long term?See historical performance and comparison
Is Merrimack Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MACK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MACK's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: MACK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MACK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MACK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MACK is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (1.5x).
How is Merrimack Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Merrimack Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MACK is currently unprofitable.
Growing Profit Margin: MACK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MACK is unprofitable, but has reduced losses over the past 5 years at a rate of 61.9% per year.
Accelerating Growth: Unable to compare MACK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MACK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MACK has a negative Return on Equity (-13.44%), as it is currently unprofitable.
How is Merrimack Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MACK's short term assets ($14.6M) exceed its short term liabilities ($564.0K).
Long Term Liabilities: MACK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MACK is debt free.
Reducing Debt: MACK currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable MACK has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: MACK is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 46.9% per year.
What is Merrimack Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MACK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MACK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MACK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MACK's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MACK has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Crocker (69 yo)
Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD105.44K) is below average for companies of similar size in the US market ($USD770.27K).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
Experienced Management: MACK's management team is seasoned and experienced (5.4 years average tenure).
Experienced Board: MACK's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MACK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Merrimack Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Merrimack Pharmaceuticals, Inc.
- Ticker: MACK
- Exchange: NasdaqGM
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$67.722m
- Shares outstanding: 13.41m
- Website: https://www.merrimack.com
Number of Employees
- Merrimack Pharmaceuticals, Inc.
- One Broadway
- 14th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.